Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665373 · ClinicalTrials.gov registry record · NA
Fitness and Nutrition in Glioma
A NA study of Malignant Glioma, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06665373: Recruiting NA study of Malignant Glioma, sponsored by NYU Langone Health.
NCT06665373 is a NA study of Malignant Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 15 participants, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06665373, a NA study of Malignant Glioma, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study assessing the effects of combining a modified Atkins diet with a physical fitness regimen in patients with malignant glioma. A sample size of 15 participants will be enrolled in a 15-week program consisting of two weekly supervised exercise sessions combined with an individualized home exercise program and a modified Atkins diet.
Primary Outcome
The SF-36
Conditions Studied
Interventions
- BEHAVIORAL Modified Atkins Diet
- BEHAVIORAL Fitness Program
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT06665373 shows while recruiting
NCT06665373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Modified Atkins Diet is the first listed.
NCT06665373 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06665373 about?
NCT06665373 is a clinical study titled "Fitness and Nutrition in Glioma". This is a pilot study assessing the effects of combining a modified Atkins diet with a physical fitness regimen in patients with malignant glioma. A sample size of 15 participants will be enrolled in a 15-week program consisting of two weekly supervised exercise sessions combined with an individuali...
What is the current status of trial NCT06665373?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-10-01. Estimated completion is 2026-10.
What conditions does trial NCT06665373 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT06665373?
The interventions under investigation include: Modified Atkins Diet (BEHAVIORAL), Fitness Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06665373?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665373 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06665373's enrollment target sits among peer trials
15 39th of 40 the lowest of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
ACTIVE NOT RECRUITING · NA
-
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
COMPLETED · NA
-
Mapping of Electrical Properties in the Brain
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI